PFIZER INC 4

Pfizer Inc. director Ronald E. Blaylock purchased 39,231 shares of Pfizer common stock on August 5, 2026 for roughly $1.0 million, increasing his direct holdings to 66,938 shares.

On August 5, 2026, Pfizer Inc. director Ronald E. Blaylock reported an open‑market purchase of 39,231 shares of Pfizer common stock at approximately $25.46 per share, for an estimated $998,000. Following this transaction, his directly held ownership increased to 66,938 shares of common stock, representing a meaningful personal capital commitment at a price near the prevailing market. In addition, a separate indirect holding of 4,750 shares of common stock is reported as held by trust, indicating an additional, though smaller, beneficial interest outside his direct account. Based on Pfizer’s current stock price of about $25.73, Blaylock’s directly held stake is now worth roughly $1.72 million, with his trust-held shares worth about $122,000, underscoring a sizeable alignment of his financial interests with those of other shareholders.

Filing Facts

CIK

78003

Ticker

PFE

Form

4

Source Type

fda

Accession

0001225208-26-006944

Alert Tier

7